Transitioning sildenafil to taladafil in PAH patients is safe

Published: Sep 1, 2015
Abstract
Background: null Phosphodiesterase type-5 inhibitors (iPDE5) are one of the mainstays of Pulmonary Arterial Hypertension (PAH) treatment. Tadalafil is an alternative to sildenafil with the advantage of a less frequent dosing (once instead of 3-times daily). null null Aim: null To examine the feasibility of transitioning PAH patients from sildenafil to taladafil. null null Methods: null We studied twenty clinically stable PAH outpatients from a...
Paper Details
Title
Transitioning sildenafil to taladafil in PAH patients is safe
Published Date
Sep 1, 2015
Journal
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.